Evidence map›Paper›PMID 38645076›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia.

Brandon-Joe Cilia, Dhamidhu Eratne, Cassandra Wannan, Charles Malpas, Shorena Janelidze, Oskar Hansson, Ian Everall, Chad Bousman, Naveen Thomas, Alexander F Santillo and 2 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Brandon-Joe CiliaNeuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.ORCID 0000-0002-7814-0471
Dhamidhu EratneNeuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.ORCID 0000-0002-3226-7645
Cassandra WannanCentre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0003-1317-4635
Charles MalpasDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0003-0534-3718
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden.ORCID 0000-0001-8467-7286
Ian EverallVisiting Professor, King's College London.
Chad BousmanDepartment of Medical Genetics, University of Calgary.ORCID 0000-0001-6303-8696
Naveen ThomasMental Health and Wellbeing Services, Western Health, St Albans VIC, Australia.ORCID 0000-0001-6876-1015
Alexander F SantilloClinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden.ORCID 0000-0001-9717-0820
Dennis VelakoulisNeuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia.
Christos PantelisMelbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0002-9565-0238
The Royal Melbourne Hospital · AULund University · SEThe University of Melbourne · AUKing's College London · GBWestern Health · AU

Funding

Prospective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settingsR01AG083740 · NIA · LUNDS UNIVERSITET · PI Sebastian Palmqvist · 2023 to 2026
$1.9M
NIA NIH HHS R01 AG083740
6 · The paper itself

Abstract

Background and Hypothesis: Around 30% of people with schizophrenia are refractory to antipsychotic treatment (treatment-resistant schizophrenia; TRS). While abnormal structural neuroimaging findings, in particular volume and thickness reductions, are often observed in schizophrenia, it is anticipated that biomarkers of neuronal injury like neurofilament light chain protein (NfL) can improve our understanding of the pathological basis underlying schizophrenia. The current study aimed to determine whether people with TRS demonstrate different associations between plasma NfL levels and regional cortical thickness reductions compared with controls. Study Design: Measurements of plasma NfL and cortical thickness were obtained from 39 individuals with TRS, and 43 healthy controls. T1-weighted magnetic resonance imaging sequences were obtained and processed via FreeSurfer. General linear mixed models adjusting for age and weight were estimated to determine whether the interaction between diagnostic group and plasma NfL level predicted lower cortical thickness across frontotemporal structures and the insula. Study Results: Significant (false discovery rate corrected) cortical thinning of the left ( Conclusions: The association between regional thickness reduction of the insula bilaterally and plasma NfL may reflect a neurodegenerative process during the course of TRS. The findings of the present study suggest that some level of cortical degeneration localised to the bilateral insula may exist in people with TRS, which is not observed in the normal population.

Indexed as

biomarkerneurofilamentneuroimagingSchizophreniatreatment-resistant

Identifiers

PMID38645076
PMCPMC11030485
OpenAlexW4394567466

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.